STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
IMGN IMMUNOGEN INCORPORATED StockScouter® Report
1
StockScouter® Score
IMMUNOGEN INCORPORATED, a mid cap growth company in the healthcare sector, is expected to slightly underperform the market over the next six months with higher than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- Earnings growth in the past year has accelerated rapidly compared to earnings growth in the past three years. Positive
Concerns
- The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
- Two or more executives, board directors or major shareholders – including one high-level executive -- sold a large number of shares recently. Very negative
- The ratio of IMGN’s forward price-to-earnings multiple to its estimated growth rate is well above the average of comparably-sized companies in the StockScouter universe. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.
Expected Risk/Return
Core Model Grades
A
F
F
B